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Abstract
Alterations in musculoskeletal health with advanced age contribute to sarcopenia and decline in bone mineral density (BMD) 
and bone strength. This decline may be modifiable via dietary supplementation. To test the hypothesis that a specific oral 
nutritional supplement can result in improvements in measures of bone health. Participants (n 380) were participants of 
the PROVIDE study, a 13-week, multicenter, randomized, controlled, double-blind, 2 parallel-group study among non-
malnourished older participants (≥ 65 years) with sarcopenia [determined by Short Physical Performance Battery (SPPB; 
0-12) scores between 4 and 9, and a low skeletal muscle mass index (SMI; skeletal muscle mass/BW × 100) ≤ 37% in men 
and ≤ 28% in women using bioelectric impedance analysis] Supplementation of a vitamin D, calcium and leucine-enriched 
whey protein drink that comprises a full range of micronutrients (active; 2/day) was compared with an iso-caloric control. 
Serum 25-hydroxyvitamin D [25(OH)D], parathyroid hormone (PTH), biochemical markers of bone formation (osteoc-
alcin; OC, procollagen type 1 amino-terminal propeptide; P1NP) and resorption (carboxy-terminal collagen crosslinks; 
CTX), insulin like growth factor 1 (IGF-1) and total-body BMD were analysed pre- and post-intervention. Serum 25(OH)
D concentrations increased from 51.1 ± 22.9 nmol/L (mean ± SD) to 78.9 ± 21.1 nmol/L in the active group (p < 0.001 vs. 
control). Serum PTH showed a significant treatment difference (p < 0.001) with a decline in the active group, and increase in 
the control group. Serum IGF-1 increased in the active group (p < 0.001 vs. control). Serum CTX showed a greater decline 
in the active group (p = 0.001 vs. control). There were no significant differences in serum OC or P1NP between groups dur-
ing the intervention. Total body BMD showed a small (0.02 g/cm2; ~ 2%) but significant increase in the active group after 
supplementation (p = 0.033 vs. control). Consuming a vitamin D, calcium and leucine-enriched whey protein supplement 
for 13 weeks improved 25(OH)D, suppressed PTH and had small but positive effects on BMD, indicative of improved bone 
health, in sarcopenic non-malnourished older adults.
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Introduction
Loss of muscle mass and function (i.e. sarcopenia), and 
decline in bone mineral density (BMD) and bone strength 
(i.e. osteopenia and osteoporosis) lead to alterations in mus-
culoskeletal health with advanced age [1]. Both disorders 
increase the risk of fractures, loss of independence, and 
mortality [2] but the risk is highest in those with so-called 
osteosarcopenia where both disorders coincide [3]. A bilat-
eral cross-talk between muscle and bone has been suggested 
[4], with underlying causal factors that partly overlap.
Like muscle, bone is a dynamic tissue that responds 
to the external and internal environments to which it is 
exposed during an individual’s lifetime. While a consid-
erable variations in bone mass is considered genetically 
determined (up to 70%), lifestyle factors such as nutri-
tion and exercise are well-established modifiable factors 
of bone mass. Of the modifiable nutritional factors, dietary 
protein, vitamin D and calcium are well known [5]. In a 
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study of 82 patients (mean age, 80.7 years) with recent 
osteoporotic hip fracture, protein deficiency was associ-
ated with accelerated bone resorption and impaired bone 
formation [6]. Adequate protein intake increases insulin-
like growth factor 1 (IGF-1) and promotes calcium absorp-
tion, potentially slowing bone loss [7]. Garnero et  al. 
reported an association between increased fracture risk 
and low-IGF-1 levels, independent of BMD, in healthy 
postmenopausal women [8]. A recent meta-analysis in 
adults (≥ 18 years) showed positive trends of higher pro-
tein intake (defined as either > 90 g protein/day, 25% and 
30% of total energy from protein/day or 1.4 g protein kg−1/
day) on lumber spine BMD [9]. Apart from the absolute 
protein intake level, there is some evidence that the intake 
of specific amino acids is associated with higher spine and 
forearm BMD, with the strongest association observed for 
leucine [10]. Moreover, dietary essential amino acid sup-
plementation in rats on a low-protein diet increased bone 
strength through significant (2–4%) increases in lumbar 
spine and tibia BMD, trabecular architecture, and cortical 
thickness, likely mediated via an increase of IGF-1 [11]. 
This is also reflected by the dietary recommendation for 
prevention of age-related deterioration of musculoskeletal 
health in postmenopausal women by The European Soci-
ety for Clinical and Economic Aspects of Osteoporosis 
and Osteoarthritis (ESCEO). The ESCEO recommends a 
daily protein intake of 1.0–1.2 g/kg with at least 20 to 
25 g of high-quality protein at each main meal, adequate 
vitamin D intake at 800 IU/day to maintain serum 25(OH)
D above 50 nmol/L as well as calcium intake of 1000 mg/
day. These recommendations for protein and vitamin D are 
in line with those from the PRO-TAGE study group [12] 
and Institute of Medicine [13] for older adults.
In a previous publication [14], we described the interven-
tion effects of a targeted nutritional supplement containing 
whey protein enriched with leucine, vitamin D, calcium 
and a full range of micronutrients on macronutrient intake 
and muscle mass and lower-extremity function in older 
sarcopenic adults. A nutritional intervention can improve 
the functional capacity in older adults with an inadequate 
nutritional status. To establish an (detectable) increase in 
muscle mass, in addition to improvement of muscle qual-
ity, a sufficient 25(OH)D status and protein intake may be 
required as we have previously shown [15]. Therefore, we 
hypothesised that providing the same nutritional interven-
tion in sarcopenic older adults would improve markers of 
musculoskeletal health. Here, we report the efficacy of this 
supplement for improving serum 25(OH)D and reducing 
parathyroid hormone (PTH) as well as altering biochemi-
cal markers of bone formation (Osteocalcin; OC, Procol-
lagen type 1 amino-terminal propeptide; P1NP), resorption 
(carboxy-terminal collagen crosslinks; CTX), serum IGF-1 
and total body BMD.
Methods
Design and Participants
Participants were members of the PROVIDE study, a 
13-week, multicenter, randomized, controlled, double-
blind, two parallel-group study among non-malnourished 
older participants (> 65 years) with mobility limitations 
and reduced muscle mass [14]. The study protocol, approv-
als and participant characteristics have been described 
in detail elsewhere [14] but in brief, participants were 
recruited from 18 study centres in 6 European countries: 
Belgium, Germany, Ireland, Italy, Sweden, and the United 
Kingdom. Participants were screened for mild to moderate 
limitations in physical function (SPPB score 4–9), and for 
low-skeletal Muscle Mass Index [SMI; (skeletal muscle 
mass/BW × 100) ≤ 37% in men and ≤ 28% in women] [1] 
using bioelectric impedance analysis (BIA 101; Akern, 
Florence, Italy) at each location [16]. Based on the work 
by Sergi et al. [17], the BIA method reports a 1% preci-
sion for resistance (Rz) and 5% precision for reactance 
(Xc). Furthermore, participants were eligible to partici-
pate if they had a body mass index (BMI) between 20 and 
30 kg/m2, no major cognitive impairment [Mini Mental 
State Examination (MMSE) score ≥ 25], and were able 
and willing to provide informed consent. Potential par-
ticipants were excluded if they had comorbidities such as 
kidney or liver failure, malignancies over the past 5 years, 
anemia, or acute inflammation (C-reactive protein concen-
tration > 10 mg/L), presented with contraindications for 
calcium/vitamin D supplementation and/or were using 
medication interfering with the nutritional intervention. 
Users of protein containing or amino acid-containing 
nutritional supplements 3 months before starting and dur-
ing the study were excluded. Moreover, throughout the 
study, participants were instructed not to change nutri-
tional habits, including nutritional supplements. With 
regard to medical use of vitamin D and calcium intake 
from medical sources, the following exclusion criteria 
applied:
• More than 22 μg (880 IU) of daily vitamin D intake 
from medical sources.
• Between 11.25 μg (450  IU) and 22 μg (880  IU) of 
daily vitamin D intake from medical sources in com-
bination with a serum calcidiol (25(OH)D; vitamin D) 
level ≥ 50 nmol/L.
• More than 500 mg of daily calcium intake from medical 
sources.
A diagnosis of osteoporosis and use of anti-osteoporo-
tic medications were not defined as exclusion criteria 
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and osteoporosis was not assessed from the DXA scans. 
Medical history for known osteoporosis at baseline indi-
cates that 10.3% of participants were osteoporotic, with 
no difference between the control and treatment groups. 
Further details on medical visits/falls, dietary assessment, 
the MMSE, Geriatric Depression Score (GDS), Physical 
Activity Scale for the Elderly (PASE), and assessment of 
appendicular muscle mass have been described previously 
[14].
Participants were randomized by permuted block rand-
omization (block size 4) to the active or control group was 
stratified for SPPB categories 4 to 6 and 7 to 9 and study 
center [14]. The randomization sequence was computer-
generated by a blinded statistician not involved in data 
collection or analysis. All investigators, study staff, and 
participants were blinded to group allocations, and the ran-
domization code was not broken until statistical modelling 
of the primary and secondary outcomes was complete. The 
active product contained, per serving, 20 g of whey protein, 
3 g of total leucine, 9 g of carbohydrates, 3 g of fat, 800 IU 
of vitamin D, 500 mg of calcium and a mixture of vitamins, 
minerals, and fibers, whereas the iso-caloric control prod-
uct did not contain any protein or micronutrients, and only 
carbohydrates, fat, and some trace elements [14]. Both were 
delivered as 40 g sachets with powder to be reconstituted 
with 100 to 150 mL water and consumed twice daily before 
breakfast and lunch to provide an adequate bolus of protein 
with these meals [14]. A more even distribution of protein 
ingestion throughout the day, providing adequate amounts 
of protein (25–30 g) per meal, has been suggested to modify 
net muscle protein balance on a 24-h basis [18]. Since break-
fast and lunch are the meals that in general do not meet the 
25–30 g protein guideline, participants were advised to take 
the supplement at breakfast and lunch. Study products were 
provided by Nutricia Research, Nutricia Advanced Medi-
cal Nutrition. Product compliance was measured using self-
completed intake diaries. Adequate compliance was defined 
as having consumed 10 of the possible 14 servings per week. 
Dietary assessment was conducted at baseline and week 13 
using 3-days prospective diet records for 2 week-days and 
1 weekend day. Additional energy and protein intakes from 
both supplements were added to the habitual 3-day intakes 
(i.e., non-supplementary intake) to assess total intakes. Food 
records were checked for completeness with participants 
during study visits and additional information was obtained 
about unclear items or amounts. Total energy, macronutrient 
and micronutrient intakes were calculated by the participat-
ing sites using site- and country-specific dietary data entry 
systems and food composition tables [14].
The study protocol was reviewed and approved by The 
Research Ethics Boards at each of the locations and was 
registered in the Dutch trials register with the identifier: 
NTR2329 (http://www.trial regis ter.nl/trial reg).
Outcome Measures
Standardized total body BMD measurement was performed 
by dual-energy X-ray absorptiometry (DXA; different mod-
els from Hologic, Bedford, MA and Lunar, Fairfield, CT). 
Daily calibration of the densitometers was performed in 
accordance with the instructions provided by the manufac-
turer. The scanning procedure was standardised across all 
study centres using a uniform protocol. All raw DXA data 
were centrally analysed by the same experienced investigator 
who was blinded for group allocation and study outcomes. 
For Hologic, the intramachine CV for BMD is 1.6%; the 
interrater CV is 1.8% [19].
Serum samples were processed from whole blood as pre-
viously described [14, 15]. All serum samples were ana-
lysed in the same lab but in several batches. Analytical test-
ing for total serum vitamin D [25(OH)D] was performed 
using chemiluminescense micro-particulate immunoassay 
(Abbott Laboratories, Wiesbaden, Germany). Serum 25(OH)
D concentrations were considered suboptimal if they were 
below 50 nmol/L [13]. Serum intact PTH concentrations 
were measured in serum using an ELISA (Intact parathy-
roid hormone, MD Biosciences Inc., St. Paul, MN 55108), 
with an intra-assay CV of 3.4%. Total calcium and albumin 
concentrations in serum were measured by an automated 
system (Instrumentation Laboratories UK Ltd, Cheshire, 
UK). Serum calcium concentrations were adjusted for albu-
min concentration. The intra-assay CV for serum calcium 
and albumin was 1.7% and 1.8%, respectively. OC levels 
were measured in serum samples using an ELISA (Metra™ 
Osteocalcin EIA Kit, Quidel Corporation, CA, USA), with 
an intra-assay CV of 6.0%. Bone turnover markers CTX and 
P1NP were measured using the Cobas e411 automated elec-
trochemiluminescent immunoassay (ECLIA) (Roche Diag-
nostics, Penzberg, Germany). The inter assay coefficients 
of variation (CVs) were < 5%. IGF-1 was also measured in 
serum samples using an ELISA. IGF-1 was assessed with a 
CLIA Immulite kit L2KGF2 (Siemens Healthcare Diagnos-
tics, Upplands Vἂsby, Sweden). Analysis was performed on 
Immulite 200-Xpi instrument and the inter- and intra-assay 
variation was 3.9% and 7.4%, respectively.
Statistical Analyses
Analyses were performed as intention-to-treat, defined as all 
participants randomized, regardless of whether they finished 
the full study protocol. Descriptive statistics [mean and SD, 
median and interquartile range (IQR), where appropriate] 
were determined for all variables. Variables were log- or 
square root-transformed to achieve near normal distribu-
tions where appropriate. Baseline characteristics of partici-
pants in the two intervention groups were compared using 
Fisher’s exact test (for categorical variables) or two-sample 
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t-tests or Mann–Whitney U test for continuous variables. 
The change from pre- to post-intervention values for the 
biochemical measures and BMD was compared between 
the active and control group using a two-sample t test. In 
addition, ANCOVA was used to test for the effect of the 
treatment on post-intervention variables while controlling 
for pre-intervention concentrations and covariates age, sex 
and study site. All tests were two-sided with a significance 
level of 5%. All statistical analyses were done using SAS 
software (version 9.4; SAS, Inc, Cary, NC).
Results
Between June 30, 2010, and May 30, 2013, 1240 older adults 
were screened for participation, 380 of whom were rand-
omized to the active or control groups. After the 13-week 
intervention, 302 participants completed all three study vis-
its (79% completion rate). The reason for drop-out of 78 
study participants are: adverse events (n = 45), a serious 
adverse event (n = 2; not related to product intake), with-
drawal of informed consent (n = 15), lost to follow up (n = 2), 
protocol deviation (participant taking calcium supplements), 
another reason (n = 13) [14]. During the RCT there was 
no significant difference in the number of adverse events 
between the test group (45 subjects; 25.0%) and the control 
group (54 subjects; 27.7%) (p = 0.562). The most commonly 
reported related adverse events were gastro-intestinal (such 
as abdominal pain and nausea) or metabolic and nutritional 
disorders (such as hyperglycaemia). No treatment-related 
serious adverse events occurred during the RCT. The mean 
age of the population at enrolment was 77.7 years (65% 
women) and living independently (87%). Baseline charac-
teristics were similar in both groups (Table 1). At baseline, 
the  % of participants with 25(OH)D concentrations below 
50 nmol/L was 51% and 53% in the control and active group, 
respectively (p > 0.05). All participants had low muscle 
mass, a mean SPPB score of 7.5, a mean BMI of 26.1 kg/
m2, and were non-malnourished based on the Mini Nutri-
tional Assessment Short-Form (99.5%). Ten per cent of the 
Table 1  Descriptive statistics comparing history, body composition, clinical outcomes and dietary intake at baseline between adults on control 
and active treatment
a p value based on a two-sample t test
b p value based on a Mann–Whitney test
*p value based on a Fisher’s exact test
Statistic Control n = 196 Active n = 184
Sex, female* n (%) 129 (65.8) 120 (65.2)
Age at screening (years)a Mean (SD) 78.1 (7.0) 77.3 (6.7)
MNA categories, screening  scoreb 0–7 points (malnutrition) n (%) 1 (0.5) 1 (0.5)
8–11 points (risk of malnu-
trition)
n (%) 19 (9.7) 15 (8.2)
12–14 points (no malnutri-
tion)
n (%) 176 (89.8) 168 (91.3)
Subjects with medical or hospital visit 3 months 
before the study*
n (%) 164 (83.7) 151 (82.1)
Subjects reporting falls 3 months before the study* n (%) 180 (91.8) 170 (92.4)
Geriatric Depression  Scaleb Median (IQR) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0)
MMSEb Median (IQR) 29.0 (28.0, 30.0) 29.0 (27.0, 30.0)
PASE  questionnairea Mean (SD) 98.0 (73.2) 101.6 (71.0)
Weight,  kga Mean (SD) 69.5 (10.9) 70.2 (11.6)
Height,  ma Mean (SD) 1.63 (0.09) 1.64 (0.10)
BMI, kg/m2a Mean (SD) 26.2 (2.8) 26.0 (2.5)
Appendicular muscle mass, kg,  DXAa Mean (SD) 17.5 (3.8) 17.9 (4.1)
Appendicular muscle mass/h2, kg/m2,DXAa Mean (SD) 6.6 (1.0) 6.6 (0.9)
Dietary energy intake (kcal/day)a Mean (SD) 1667.1 (401.3) 1756.7 (456.3)
Protein intake (g/day)b Median (IQR) 67 (56, 78) 70 (58, 83)
Protein intake (g/kg/day)b Median (IQR) 1.0 (0.8, 1.2) 1.0 (0.9, 1.2)
Protein intake, energy %b Median (IQR) 17 (15, 19) 16 (15, 19)
Vitamin D intake (µg)a Mean (SD) 3.5 (4.7) 3.1 (3.0)
Ca2 + (mmol/L)a Mean (SD) 2.36 (0.15) 2.34 (0.11)
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participants reported osteoporosis in their medical history, 
similar in both groups. Intervention compliance was high 
(median: 93%) from baseline to follow-up, and did not differ 
between treatment groups. Body weight increased equally 
and significantly (by ~ 1 kg) over the 13-week intervention 
in both active and control treatment groups [data not shown] 
[14].
Total body BMD increased in the active group only, 
and the improvement was significantly different from con-
trol (p = 0.033) (Table 2). Serum 25(OH)D concentrations 
increased on average by 26 nmol/L (p < 0.001) in the active 
group and decreased on average by 6 nmol/L in the control 
group after 13 weeks (Table 2). The prevalence of serum 
25(OH)D concentration below 50 nmol/L decreased from 
53 to 8% in the active group, whilst the proportion of those 
in the control group with serum 25(OH)D below 50 nmol/L 
did not decrease during the study (51% at baseline and 66% 
at week 13). Serum PTH concentrations showed significant 
treatment differences (p < 0.001) with decreased concentra-
tions in the active treatment group and increased concentra-
tions in the control group after 13 weeks (Table 2). Changes 
in serum CTX concentrations were significantly different 
Table 2  Biochemical measures 
of vitamin D status, bone 
turnover, IGF-1 and BMD 
among treatment groups before 
and after intervention
Values represent means and standard deviations
PTH parathyroid hormone, 25(OH)D 25-hydroxyvitamin D, OC osteocalcin, CTx carboxyterminal cross-
linked telopeptide of type 1 collagen
a The change from pre- to post-intervention values was compared between the active and control group 
using a two-sample t test (equal variances assumed)
b Analysis of covariance which controlled for pre-intervention concentration of the variable as well as age 
and sex with a random effect for site (small sites combined)
c Baseline measurement (measurement at screening for subjects with no baseline data), prior to first intake 
of the investigational product
d Measurement after 13 weeks of intake of the investigational product
e The data were log transformed for the statistical tests to obtain a better approximation of the normal distri-
bution based on visual inspection of the residuals of the ANCOVA models
Treatment group
Control n = 196 Active n = 184 p-value for change, 
active versus  controla
p-value 
further 
 adjustedb
Serum 25(OH)D (nmol/L)
 Pre-interventionc 52.01 (23.03) 51.05 (22.86)
 Post-interventiond 46.06 (21.40) 78.89 (21.06) < .001e < .001e
Serum PTH (pmol/L)
 Pre-interventionc 6.75 (4.67) 6.82 (4.05)
 Post-interventiond 7.30 (5.07) 5.39 (2.38) < .001e < .001e
Serum OC (μg/L)
 Pre-interventionc 4.51 (3.79) 4.63 (3.67)
 Post-interventiond 5.27 (4.50) 4.65 (3.65) 0.108e 0.099e
Serum P1NP (ng/ml)
 Pre-interventionc 52.44 (33.14) 49.67 (27.39)
 Post-interventiond 54.53 (44.95) 50.63 (27.85) 0.096 0.119
Serum CTx (ng/ml)
 Pre-interventionc 0.29 (0.20) 0.28 (0.22)
 Post-interventiond 0.27 (0.25) 0.24 (0.23) < .001 0.001
Serum IGF-1 (μg/L)
 Pre-interventionc 124.03 (73.28) 113.99 (42.55)
 Post-interventiond 119.40 (75.00) 126.46 (48.94) < .001 < .001
Serum Ca (corrected for albumin)
 Pre-interventionc 2.31 (0.15) 2.29 (0.12)
 Post-interventiond 2.31 (0.16) 2.33 (0.13) < .001 < .001
Bone mineral density (g/cm2)
 Pre-interventionc 1.07 (0.19) 1.07 (0.19)
 Post-interventiond 1.07 (0.23) 1.09 (0.18) 0.033 0.033
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(p < 0.001) between the two interventions, with lower values 
in both treatment groups after 13 weeks, but the decline was 
more marked in the active treatment group. Serum calcium 
(corrected for albumin) increased slightly after 13 weeks in 
the active treatment group only (p < 0.001; Table 2). Serum 
IGF-1 change during intervention was significantly differ-
ent between active and control groups (p < 0.001; Table 2) 
with decreased concentrations in the control group and 
significantly increased concentrations in the active group. 
There were no statistical significant treatment differences in 
change from pre- to post-intervention values in serum OC 
and P1NP. Analyses corrected for age, sex and study site 
showed very similar and consistent results (Table 2).
Discussion
The findings of this 13-week nutritional intervention among 
non-malnourished older sarcopenic adults showed important 
improvements in vitamin D status (by 55%), decreased PTH 
(by 21%) and increased IGF-1 (by 11%) concentrations in 
those participants who consumed the vitamin D (1600 IU/
day), calcium (1000 mg/day), and leucine-enriched whey 
protein (40 g/day whey protein and 6 g/day total leucine) 
supplement. In addition, concentrations of the bone resorp-
tion marker CTX declined in both treatment groups although 
the decline was more pronounced in the active group. We 
postulate that the ***reduction in CTX in the control group 
[and to some degree in the active treatment group] might be 
explained by an increase in energy intake (and thus energy 
availability) over the 13 weeks in the participants.
Mean daily energy intake increased by 166 kcal/day 
and 165 kcal/day during the 13 weeks intervention period 
in the active and control groups, respectively [14]. A 
dose–response inverse relationship between energy avail-
ability and bone resorption has been demonstrated in young 
adult women [20] and dietary energy restriction leads to 
raised bone resorption in post-menopausal women [21]. 
Validating our assumption is the fact that participants on 
control and active treatment gained approximately 1 kg dur-
ing the intervention suggesting a net positive energy balance 
in the study participants. Circulating concentrations of bone 
formation markers OC and P1NP did not change in either 
group during the intervention. Despite the lack of change in 
bone formation markers with active treatment, the observed 
large increase in circulating 25(OH)D (> 30 nmol/l) and con-
comitant reduction in PTH concentration in those partici-
pants receiving active treatment may have potential benefits 
to bone health. Indeed, consumption of the active product 
showed small but significant improvements in total body 
BMD after 13 weeks of treatment in comparison to those 
on the control product. However, whether the observed 
changes in total body BMD are transient or sustained after 
supplementation remains unclear. The observed difference in 
IGF-1 concentrations between the treatment groups may also 
offer some explanation as to why those receiving active treat-
ment had significantly higher BMD after the intervention. 
It is known that IGF-1 regulates key signalling pathways in 
bone including those involved in cell survival, protein syn-
thesis and energy utilization [22], thus potentially mediating 
the apparent positive effect of protein supplementation on 
BMD. Although serum calcium adjusted for albumin was 
lower in the active treatment group at baseline, a small statis-
tically significant increase was observed in those participants 
on active treatment after 13 weeks. All serum calcium values 
remained within the normal range on the 13-weeks supple-
mentation. Moreover, no (serious) adverse events point at 
hypercalcemia were recorded during the study.
Similar nutritional interventions in older adults support 
combined protein and vitamin D/calcium supplementa-
tion in ameliorating bone turnover but in particular bone 
resorption. In a study of 89 vitamin D deficient institu-
tionalized women ≥ 60 years old living in 10 French nurs-
ing homes, Bonjour et al. [23] observed a 20% decrease 
in PTH and an 8% decrease in CTX after consumption 
of a vitamin D (400 IU) and calcium-fortified (800 mg) 
yoghurt twice daily, over 56 days. These effects are simi-
lar to the active intervention in our study that resulted in 
a 21% and 14% decrease of PTH and CTX, respectively. 
A significant decline in PTH and bone resorption mark-
ers was also observed after 84 days of vitamin D (400 IU) 
and calcium-fortified (800  mg) yoghurt consumption 
twice daily in a community-dwelling population of 57 
women aged > 60 years, (mean age 73 years, BMI 30 kg/
m2) living in a sheltered accommodation housing in Hull 
(England) [24]. Similar effects of calcium and/or vitamin 
D fortified milk on bone parameters have been observed 
in Asian populations. A 16-weeks calcium or calcium/
vitamin D fortified milk trial in post-menopausal Asian 
women demonstrated reductions in PTH and bone turnover 
of about 10% and ≥ 20% respectively [25, 26]. Two longer 
term intervention studies with a duration between 18 and 
30 months using vitamin D fortified dairy with or without 
calcium have shown beneficial effects on bone turnover 
and/or total and site-specific BMD in postmenopausal 
women [26, 27]. In an 18-month placebo-controlled ran-
domized intervention in post-menopausal Chinese women 
receiving calcium-fortified milk, providing 900 mg calcium 
and 256 IU vitamin D daily, BMD at the hip was improved 
by ~ 2% with treatment, but no change was observed at the 
lumbar spine [26]. Total body BMD was maintained in 50 
post-menopausal women over 30 months when provided 
calcium/vitamin D fortified dairy foods (~ 1200 mg cal-
cium and 300 IU vitamin D) daily, relative to a decline in 
BMD in the control group (0.3% vs. − 1.8%) [27]. These 
alterations in BMD are comparable to those observed 
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in our study, i.e. ~ 2% increase in BMD. One possibility 
which may explain the improvement in BMD observed in 
the active treatment group after 13 weeks in our study is 
the concomitant improvement seen in IGF-1 concentrations 
after protein supplementation. IGF-1 is a growth-promot-
ing protein that plays essential roles in growth and develop-
ment including influencing skeletal growth in all stages of 
life. It is well known that the secretion IGF-1 declines dur-
ing adulthood to older age until only low levels are detected 
in adults ≥ 60 years however, the biological significance of 
this decline is unclear. Whilst the precise mechanism by 
which circulating IGF-1 functions to maintain bone mass 
is not fully understood, evidence suggests that circulating 
IGF-1 is strongly and positively associated with BMD at 
several sites in older women from the Framingham cohort 
[28]. Moreover, IGF-1 can also be considered as the cross 
road of the nutritional, inflammatory and hormonal path-
ways in the frailty process [29] and one of the main actors 
of the cross-talk between bone and muscle [4].
The improvement in total body BMD in this study com-
pliments the improvements previously observed in muscle 
mass and lower-extremity function in the same study [14], 
and adds further support to the hypothesis that osteopenia 
and sarcopenia are inextricably linked [30]. Moreover, the 
observations in this study may offer a potential benefit for 
older people at risk of fragility fractures. The 13-weeks 
intervention phase in this study, although sufficient to 
observe changes in bone resorption markers, may not have 
been long enough to detect corresponding changes in bone 
formation. In addition, we cannot conclude whether the 
beneficial intervention effects on bone are due to high 
protein, high leucine, vitamin D, calcium and/or other 
micronutrients in the active treatment such as magnesium 
and phosphorus which have a well-established role in 
bone metabolism or indeed whether there is a ‘synergistic 
effect’ due to the combination of bone related nutrients in 
the active product. Despite the relatively high phospho-
rus content of the supplement it is our view that given 
the likelihood of suboptimal dietary intakes of vitamin D 
and protein in these participants [and the general geriatric 
population] the positive effects on vitamin D status, PTH, 
IGF-1 and BMD observed in the active treatment group is 
most likely due to a combination of vitamin D and protein 
supplementation. Analysing the nutritional intake of a sub-
set of the PROVIDE study participants [31], it appeared 
that the dietary intake of phosphorus was sufficient (mean 
intakes = 1196 mg/day, which are well above current ref-
erence intakes) suggesting that additional phosphorus to 
already replete phosphorus diets may not be a large con-
tributor to the positive effects on bone health in this study.
In conclusion, consuming a vitamin D, calcium and 
leucine- enriched whey protein supplement for 13 weeks 
improved vitamin D status, suppressed serum PTH and 
had small but significant effects on BMD in sarcopenic 
non-malnourished older adults. This study shows proof-
of-principle that a specific nutritional intervention alone 
might benefit vitamin D status and bone health in older 
adults.
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